View in EDS HTML Full Text PDF Full Text

Serum concentrations of aminoacylase 1 in schizophrenia as a potential biomarker: a case-sibling-control study.

Saved in:
Bibliographic Details
Title: Serum concentrations of aminoacylase 1 in schizophrenia as a potential biomarker: a case-sibling-control study.
Authors: Göverti, Diğdem (AUTHOR), Yüksel, Rabia Nazik (AUTHOR), Kaya, Hasan (AUTHOR), Büyüklüoğlu, Nihan (AUTHOR), Yücel, Çiğdem (AUTHOR), Göka, Erol (AUTHOR)
Source: Nordic Journal of Psychiatry. Jul2022, Vol. 76 Issue 5, p380-385. 6p.
Subjects: Biomarkers, Schizophrenia, Proteolysis, Disease duration, People with schizophrenia, Amisulpride
Abstract: Aminoacylase 1 (ACY1) catalyzes the hydrolysis reaction during protein degradation. N-acetylamino acids are accumulated in the urine in Aminoacylase 1 deficiency (ACY1D). This study attempts to evaluate the potential of ACY1 as a biomarker for schizophrenia and predict genetic vulnerability in the high-risk population. Seventy patients with schizophrenia, twenty-five of which have newly diagnosed, forty-nine unaffected siblings of patients, and fifty-six healthy controls were included in the study. The ELISA method was used to measure serum ACY1. The Positive and Negative Syndrome Scale (PANSS) and The Clinical Global Impression – Severity scale (CGI-S) were used to analyze the severity of the symptoms. Data were analysed statistically by non-parametric tests. The finding of the study indicated that the serum levels of ACY1 in patients and siblings were lower compared to healthy controls (p < 0.001 and p = 0.023). There was no statistically significant difference between patients and siblings (p = 0.067). The duration of disease, PANSS total scores, and CGI-S scores did not have a significant association with the ACY1 levels in the patient group (p > 0.005). ACY1 levels among the drug-using patient group and the newly diagnosed patient group showed no notable difference (respectively, p = 0.120 and p = 0.843). This study is the first to evaluate the serum ACY1 levels in patients with schizophrenia. The result of the study provides us insight regarding the first hints that ACY1 might be a potential biomarker. Being aware of the molecule will pave the way for further explorations in the field. [ABSTRACT FROM AUTHOR]
Copyright of Nordic Journal of Psychiatry is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 157868958
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Serum concentrations of aminoacylase 1 in schizophrenia as a potential biomarker: a case-sibling-control study.
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22G&#246;verti%2C+Diğdem%22&quot;&gt;G&#246;verti, Diğdem&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Y&#252;ksel%2C+Rabia+Nazik%22&quot;&gt;Y&#252;ksel, Rabia Nazik&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Kaya%2C+Hasan%22&quot;&gt;Kaya, Hasan&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22B&#252;y&#252;kl&#252;oğlu%2C+Nihan%22&quot;&gt;B&#252;y&#252;kl&#252;oğlu, Nihan&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Y&#252;cel%2C+&#199;iğdem%22&quot;&gt;Y&#252;cel, &#199;iğdem&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22G&#246;ka%2C+Erol%22&quot;&gt;G&#246;ka, Erol&lt;/searchLink&gt; (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: &lt;searchLink fieldCode=&quot;JN&quot; term=&quot;%22Nordic+Journal+of+Psychiatry%22&quot;&gt;Nordic Journal of Psychiatry&lt;/searchLink&gt;. Jul2022, Vol. 76 Issue 5, p380-385. 6p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Biomarkers%22&quot;&gt;Biomarkers&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Schizophrenia%22&quot;&gt;Schizophrenia&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Proteolysis%22&quot;&gt;Proteolysis&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Disease+duration%22&quot;&gt;Disease duration&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22People+with+schizophrenia%22&quot;&gt;People with schizophrenia&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Amisulpride%22&quot;&gt;Amisulpride&lt;/searchLink&gt;
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Aminoacylase 1 (ACY1) catalyzes the hydrolysis reaction during protein degradation. N-acetylamino acids are accumulated in the urine in Aminoacylase 1 deficiency (ACY1D). This study attempts to evaluate the potential of ACY1 as a biomarker for schizophrenia and predict genetic vulnerability in the high-risk population. Seventy patients with schizophrenia, twenty-five of which have newly diagnosed, forty-nine unaffected siblings of patients, and fifty-six healthy controls were included in the study. The ELISA method was used to measure serum ACY1. The Positive and Negative Syndrome Scale (PANSS) and The Clinical Global Impression – Severity scale (CGI-S) were used to analyze the severity of the symptoms. Data were analysed statistically by non-parametric tests. The finding of the study indicated that the serum levels of ACY1 in patients and siblings were lower compared to healthy controls (p &lt; 0.001 and p = 0.023). There was no statistically significant difference between patients and siblings (p = 0.067). The duration of disease, PANSS total scores, and CGI-S scores did not have a significant association with the ACY1 levels in the patient group (p &gt; 0.005). ACY1 levels among the drug-using patient group and the newly diagnosed patient group showed no notable difference (respectively, p = 0.120 and p = 0.843). This study is the first to evaluate the serum ACY1 levels in patients with schizophrenia. The result of the study provides us insight regarding the first hints that ACY1 might be a potential biomarker. Being aware of the molecule will pave the way for further explorations in the field. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: &lt;i&gt;Copyright of Nordic Journal of Psychiatry is the property of Taylor &amp; Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder&#39;s express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.&lt;/i&gt; (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=157868958
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/08039488.2021.1981435
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 6
        StartPage: 380
    Subjects:
      – SubjectFull: Biomarkers
        Type: general
      – SubjectFull: Schizophrenia
        Type: general
      – SubjectFull: Proteolysis
        Type: general
      – SubjectFull: Disease duration
        Type: general
      – SubjectFull: People with schizophrenia
        Type: general
      – SubjectFull: Amisulpride
        Type: general
    Titles:
      – TitleFull: Serum concentrations of aminoacylase 1 in schizophrenia as a potential biomarker: a case-sibling-control study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Göverti, Diğdem
      – PersonEntity:
          Name:
            NameFull: Yüksel, Rabia Nazik
      – PersonEntity:
          Name:
            NameFull: Kaya, Hasan
      – PersonEntity:
          Name:
            NameFull: Büyüklüoğlu, Nihan
      – PersonEntity:
          Name:
            NameFull: Yücel, Çiğdem
      – PersonEntity:
          Name:
            NameFull: Göka, Erol
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: Jul2022
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-print
              Value: 08039488
          Numbering:
            – Type: volume
              Value: 76
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: Nordic Journal of Psychiatry
              Type: main
ResultId 1